24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
@Finance
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Compugen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:42
Zim $4.5 billion bidder faces foreclosure on his home
21:25
NextVision insiders cash out $200 million in share sale
21:14
"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"
20:27
Electra Real Estate CEO: “The $7 trillion US rental housing market is the place to be”
More stories
Buzz
Most popular
Daily
Weekly
1
Jewish family from Mexico donates NIS 200 million to establish Israel's largest rehabilitation hospital
2
After raising $20 million, collapsed startup Swish.ai sells to Unframe for just $150,000
3
Echo: “Employees have become very good at identifying performative culture”
4
After PTSD and years of insomnia, Israeli founder raises $6.5 million to improve sleep through scent
5
More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life
More news
Compugen
5 stories about Compugen
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Compugen Falls 17% on Employee Cuts Announcement
27.02.19
|
Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18
|
Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering
17.06.18
|
Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen